|
1
|
Vigneri R, Malandrino P and Vigneri P: The
changing epidemiology of thyroid cancer: Why is incidence
increasing? Curr Opin Oncol. 27:1–7. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
2
|
Mazeh H and Chen H: Advances in surgical
therapy for thyroid cancer. Nat Rev Endocrinol. 7:581–588. 2011.
View Article : Google Scholar : PubMed/NCBI
|
|
3
|
Suzuki MM and Bird A: DNA methylation
landscapes: Provocative insights from epigenomics. Nat Rev Genet.
9:465–476. 2008. View
Article : Google Scholar : PubMed/NCBI
|
|
4
|
Wu YC and Ling ZQ: The role of TET family
proteins and 5-hydroxymethylcytosine in human tumors. Histol
Histopathol. 29:991–997. 2014.PubMed/NCBI
|
|
5
|
Lian CG, Xu Y, Ceol C, Wu F, Larson A,
Dresser K, Xu W, Tan L, Hu Y, Zhan Q, et al: Loss of
5-hydroxymethylcytosine is an epigenetic hallmark of melanoma.
Cell. 150:1135–1146. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
6
|
Ito S, D'Alessio AC, Taranova OV, Hong K,
Sowers LC and Zhang Y: Role of Tet proteins in 5mC to 5hmC
conversion, ES-cell self-renewal and inner cell mass specification.
Nature. 466:1129–1133. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
7
|
Tahiliani M, Koh KP, Shen Y, Pastor WA,
Bandukwala H, Brudno Y, Agarwal S, Iyer LM, Liu DR, Aravind L and
Rao A: Conversion of 5-methylcytosine to 5-hydroxymethylcytosine in
mammalian DNA by MLL partner TET1. Science. 324:930–935. 2009.
View Article : Google Scholar : PubMed/NCBI
|
|
8
|
Liu X, Zhang G, Yi Y, Xiao L, Pei M, Liu
S, Luo Y, Zhong H, Xu Y, Zheng W and Shen J: Decreased
5-hydroxymethylcytosine levels are associated with TET2 mutation
and unfavorable overall survival in myelodysplastic syndromes. Leuk
Lymphoma. 54:2466–2473. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
9
|
Munari E, Chaux A, Vaghasia AM, Taheri D,
Karram S, Bezerra SM, Gonzalez Roibon N, Nelson WG,
Yegnasubramanian S, Netto GJ and Haffner MC: Global
5-hydroxymethylcytosine levels are profoundly reduced in multiple
genitourinary malignancies. PLoS One. 11:e01463022016. View Article : Google Scholar : PubMed/NCBI
|
|
10
|
Qiu L, Liu F, Yi S, Li X, Liu X, Xiao C,
Lian CG, Tu P and Wang Y: Loss of 5-hydroxymethylcytosine is an
epigenetic biomarker in cutaneous T cell lymphoma. J Invest
Dermatol. 138:2388–2397. 2018. View Article : Google Scholar : PubMed/NCBI
|
|
11
|
Mancikova V, Buj R, Castelblanco E,
Inglada-Pérez L, Diez A, de Cubas AA, Curras-Freixes M, Maravall
FX, Mauricio D, Matias-Guiu X, et al: DNA methylation profiling of
well-differentiated thyroid cancer uncovers markers of recurrence
free survival. Int J Cancer. 135:598–610. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
12
|
Paulsen IM, Dimke H and Frische S: A
single simple procedure for dewaxing, hydration and heat-induced
epitope retrieval (HIER) for immunohistochemistry in formalin fixed
paraffin-embedded tissue. Eur J Histochem. 59:25322015. View Article : Google Scholar : PubMed/NCBI
|
|
13
|
Bhutani N, Burns DM and Blau HM: DNA
demethylation dynamics. Cell. 146:866–872. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
14
|
Esteller M: Epigenetics in cancer. N Engl
J Med. 358:1148–1159. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
15
|
Jones PA and Baylin SB: The epigenomics of
cancer. Cell. 128:683–692. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
16
|
Hemberger M, Dean W and Reik W: Epigenetic
dynamics of stem cells and cell lineage commitment: Digging
Waddington's canal. Nat Rev Mol Cell Biol. 10:526–537. 2009.
View Article : Google Scholar : PubMed/NCBI
|
|
17
|
Kohli RM and Zhang Y: TET enzymes, TDG and
the dynamics of DNA demethylation. Nature. 502:472–479. 2013.
View Article : Google Scholar : PubMed/NCBI
|
|
18
|
Shen L and Zhang Y:
5-Hydroxymethylcytosine: Generation, fate, and genomic
distribution. Curr Opin Cell Biol. 25:289–296. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
19
|
Rasmussen KD and Helin K: Role of TET
enzymes in DNA methylation, development, and cancer. Genes Dev.
30:733–750. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
20
|
Li W, Zhang X, Lu X, You L, Song Y, Luo Z,
Zhang J, Nie J, Zheng W, Xu D, et al: 5-Hydroxymethylcytosine
signatures in circulating cell-free DNA as diagnostic biomarkers
for human cancers. Cell Res. 27:1243–1257. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
21
|
Yang H, Liu Y, Bai F, Zhang JY, Ma SH, Liu
J, Xu ZD, Zhu HG, Ling ZQ, Ye D, et al: Tumor development is
associated with decrease of TET gene expression and
5-methylcytosine hydroxylation. Oncogene. 32:663–669. 2013.
View Article : Google Scholar : PubMed/NCBI
|
|
22
|
Haffner MC, Chaux A, Meeker AK, Esopi DM,
Gerber J, Pellakuru LG, Toubaji A, Argani P, Iacobuzio-Donahue C,
Nelson WG, et al: Global 5-hydroxymethylcytosine content is
significantly reduced in tissue stem/progenitor cell compartments
and in human cancers. Oncotarget. 2:627–637. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
23
|
Jin SG, Jiang Y, Qiu R, Rauch TA, Wang Y,
Schackert G, Krex D, Lu Q and Pfeifer GP: 5-Hydroxymethylcytosine
is strongly depleted in human cancers but its levels do not
correlate with IDH1 mutations. Cancer Res. 71:7360–7365. 2011.
View Article : Google Scholar : PubMed/NCBI
|
|
24
|
Kudo Y, Tateishi K, Yamamoto K, Yamamoto
S, Asaoka Y, Ijichi H, Nagae G, Yoshida H, Aburatani H and Koike K:
Loss of 5-hydroxymethylcytosine is accompanied with malignant
cellular transformation. Cancer Sci. 103:670–676. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
25
|
Ko M, Huang Y, Jankowska AM, Pape UJ,
Tahiliani M, Bandukwala HS, An J, Lamperti ED, Koh KP, Ganetzky R,
et al: Impaired hydroxylation of 5-methylcytosine in myeloid
cancers with mutant TET2. Nature. 468:839–843. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
26
|
Kraus TF, Globisch D, Wagner M, Eigenbrod
S, Widmann D, Münzel M, Müller M, Pfaffeneder T, Hackner B, Feiden
W, et al: Low values of 5-hydroxymethylcytosine (5hmC), the ‘sixth
base,’ are associated with anaplasia in human brain tumors. Int J
Cancer. 131:1577–1590. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
27
|
Kanwal R and Gupta S: Epigenetic
modifications in cancer. Clin Genet. 81:303–311. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
28
|
Zafon C, Baena JA, Castellvi J, Obiols G,
Monroy G and Mesa J: Differences in the form of presentation
between papillary microcarcinomas and papillary carcinomas of
larger size. J Thyroid Res. 2011:6391562010.PubMed/NCBI
|
|
29
|
Schneider DF and Chen H: New developments
in the diagnosis and treatment of thyroid cancer. CA Cancer J Clin.
63:374–394. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
30
|
Ito Y, Miyauchi A, Inoue H, Fukushima M,
Kihara M, Higashiyama T, Tomoda C, Takamura Y, Kobayashi K and Miya
A: An observational trial for papillary thyroid microcarcinoma in
Japanese patients. World J Surg. 34:28–35. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
31
|
Londero SC, Krogdahl A, Bastholt L,
Overgaard J, Trolle W, Pedersen HB, Bentzen J, Schytte S,
Christiansen P and Godballe C; Danish Thyroid Cancer Group, :
Papillary thyroid microcarcinoma in Denmark 1996–2008: A national
study of epidemiology and clinical significance. Thyroid.
23:1159–1164. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
32
|
Jeong SY, Baek JH, Choi YJ, Chung SR, Sung
TY, Kim WG, Kim TY and Lee JH: Radiofrequency ablation of primary
thyroid carcinoma: Efficacy according to the types of thyroid
carcinoma. Int J Hyperthermia. 34:611–616. 2018. View Article : Google Scholar : PubMed/NCBI
|
|
33
|
Zhang M, Luo Y, Zhang Y and Tang J:
Efficacy and safety of ultrasound-guided radiofrequency ablation
for treating low-risk papillary thyroid microcarcinoma: A
prospective study. Thyroid. 26:1581–1587. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
34
|
Haugen BR, Alexander EK, Bible KC, Doherty
GM, Mandel SJ, Nikiforov YE, Pacini F, Randolph GW, Sawka AM,
Schlumberger M, et al: 2015 American thyroid association management
guidelines for adult patients with thyroid nodules and
differentiated thyroid cancer: The American thyroid association
guidelines task force on thyroid nodules and differentiated thyroid
cancer. Thyroid. 26:1–133. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
35
|
Chereau N, Oyekunle TO, Zambeli-Ljepović
A, Kazaure HS, Roman SA, Menegaux F and Sosa JA: Predicting
recurrence of papillary thyroid cancer using the eighth edition of
the AJCC/UICC staging system. Br J Surg. 106:889–897. 2019.
View Article : Google Scholar : PubMed/NCBI
|
|
36
|
Figueroa ME, Abdel-Wahab O, Lu C, Ward PS,
Patel J, Shih A, Li Y, Bhagwat N, Vasanthakumar A, Fernandez HF, et
al: Leukemic IDH1 and IDH2 mutations result in a hypermethylation
phenotype, disrupt TET2 function, and impair hematopoietic
differentiation. Cancer Cell. 18:553–567. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
37
|
Plongthongkum N, Diep DH and Zhang K:
Advances in the profiling of DNA modifications: Cytosine
methylation and beyond. Nat Rev Genet. 15:647–661. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
38
|
Shim EH, Livi CB, Rakheja D, Tan J, Benson
D, Parekh V, Kho EY, Ghosh AP, Kirkman R, Velu S, et al:
L-2-Hydroxyglutarate: An epigenetic modifier and putative
oncometabolite in renal cancer. Cancer Discov. 4:1290–1298. 2014.
View Article : Google Scholar : PubMed/NCBI
|
